Reports
Our ambition is to be transparent and ensure that our information to investors and the media meets the highest quality standards.
Please don’t hesitate to contact us if you have any questions: ir@episurf.com.
All reports below are a translation of the original Swedish report. In the event of a discrepancy between this translation and the Swedish original, the Swedish reports take precedence. The English version of the Annual Report is not the official version and is not reported according to ESEF.
Episurf Medical AB (publ) (Nasdaq: EPIS B) today publishes its interim report for January–June 2026. Rental income increased by 257 per cent to SEK 17.5 (4.9) mn. At the end of the period, the property portfolio comprised 39 (1) properties with a lettable area of 61,456 (4,529) square metres and a market value of SEK 946 (108) mn. The period in brief Rental income amounted to SEK 17.5 (4.9) mn for the half-year and SEK…
Episurf Medical begins transformation into a cash flow-oriented property company Episurf Medical AB (publ) (Nasdaq: EPIS B) today publishes its interim report for the period 1 January – 31 March 2026. The first quarter marked the beginning of the company’s transformation into a cash flow-oriented property company, with the first property acquisitions completed at an underlying property value of approximately SEK 270m. “The first quarter of 2026 marked the beginning of Episurf’s transformation into a…
First quarter 2026 compared to 2025, Group Group net sales amounted to SEK 8.8m (2.5) Loss for the period amounted to SEK -26.9m (1.5) Loss per share amounted to SEK -0.01 (-0.00) Group cash and cash equivalents at end of period amounted to SEK 12.2m (5.7) Equity ratio of 76.8% (32.7) Significant events during the first quarter 2026 On January 26, Episurf entered into an agreement to acquire a property portfolio with an underlying property…
Episurf Medical’s annual report for 2025 is available as of today at the company’s website, www.episurf.com. Episurf Medical has of environmental and cost reasons chosen not to print the annual report. A printed version of the annual report will be distributed to shareholders and others who made such request. The annual report can also be ordered from Episurf Medical on the following address: Episurf Medical AB, Karlavägen 60, 114 49 Stockholm, Sweden or by email: ir@episurf.com. For further information, please contact: Jens Andersson, CEO, Episurf Medical Email: jens.andersson@episurf.com Sanja Batljan, CFO, Episurf Medical Email: sanja.batljan@episurf.com About Episurf Medical AB …
Significant company transformation through the purchase of real estate and continued progress in the medical device business “We have taken significant steps forward in 2025. For the fourth quarter, we show both increased order intake and revenue, while considerably reducing our operating costs, compared to the same quarter in 2024. Gross order intake for the quarter increased by 13% to SEK 3.5 million and the trend for the fourth quarter follows what we have seen earlier…
Strong US growth in gross-order intake and customer base Significantly improved financial results Continued focus on regulatory pathway for MTP-implant “This is my first CEO statement as CEO of Episurf Medical, although I have been with the company since its inception. I will work hard to ensure that we achieve our goals, and I fully support our strategy to drive sales in our most important markets, achieve FDA clearance for our toe implant Episealer® MTP,…
• Improved results of SEK 7.0m adjusted for re-structuring provision of SEK 3.1m, with additional cost savings identified • More than 100% growth in the U.S. customer base and continued expansion of the U.S. distributor network, with a 46% increase in order intake during the first half of the year in the U.S. • Ongoing establishment of European distribution operations through collaboration with Joint Operations “During the second quarter, we made significant changes to our…
• Continued increases in sales and gross order intake combined with lower expense level • Significant increase in European sales organisation through co-operation with Joint Operations • First surgeries together with Johnson & Johnson-affiliated distributors successfully completed “It is gratifying that we continue to show growth while reporting significant improvements in costs and in results. We are undergoing a major transformation in Europe with our recent agreement with Joint Operations, which has some negative impact…
Episurf Medical’s annual report for 2024 is available as of today at the company’s website, www.episurf.com. Episurf Medical has of environmental and cost reasons chosen not to print the annual report. A printed version of the annual report will be distributed to shareholders and others who made such request. The annual report can also be ordered from Episurf Medical on the following address: Episurf Medical AB, Karlavägen 60, 114 49 Stockholm, Sweden or by email: ir@episurf.com.